GVB has been acquired by 22nd Century Group (Nasdaq: XXII), Read the Press Release Here

Cart (0 item)

Archives: Press Releases

22nd Century Group

Immediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA

1,276 Novel Food Applications for Cannabinoid Products to Accelerate Growth in the U.K. and EU Food and Nutraceuticals Markets

  • Posted in
  • Comments Off on 22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position
GVB 22nd Century Group

Partnership Will Provide Pharmaceutical Grade Cannabinoid Active Ingredients to the Largest Pharmaceutical and Consumer Goods Names in the Industry

  • Posted in
  • Comments Off on 22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs
GVB 22nd Century Group

Customer shipments continue uninterrupted, expects to resume production within weeks.

  • Posted in
  • Comments Off on 22nd Century Group Provides Update on Grass Valley Facility
GVB 22nd Century Group

Established backup plans implemented to ensure continuous customer delivery.

  • Posted in
  • Comments Off on 22nd Century Group Provides Update on Incident at Grass Valley Facility
GVB Biopharma CBG

New distribution facility supports rapidly growing demand for hemp/cannabis products

  • Posted in
  • Comments Off on 22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands

Complete Hemp/Cannabis Solution from Receptor Science and Plant Genetics to Final Ingredients and CDMO.

  • Posted in
  • Comments Off on 22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform

Provides Transformational Platform to Rapidly Grow Hemp/Cannabis Franchise & Adds Significant Commercial Scale to Existing Hemp/Cannabis Franchise

  • Posted in
  • Comments Off on 22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis Company

LONDON, UK, April 7, 2022 – GVB Biopharma, a biopharmaceutical company specializing in hemp and cannabis-related white-label consumer products, announced today that all of its products remain approved by the Food Standards Agency (FSA) after the organization created stricter market standards for foods containing cannabidiol (CBD) sold in most United Kingdom (UK) countries. On April 1, […]

  • Posted in
  • Comments Off on All GVB Biopharma Products Clear New, Stricter Food Safety Standards in UK

LAS VEGAS, March 30, 2022 — GVB Biopharma, a biopharmaceutical company specializing in hemp and cannabis-related white-label consumer products, announced today that its website has launched sales of cannabigerolic acid isolates, popularly known as CBGa. CBGa is the carboxylic acid form of cannabigerol, known as CBG. It is a precursor molecule to delta-9-tetrahydrocannabinol, one of […]

  • Posted in
  • Comments Off on GVB Biopharma Begins Sales of CBGa Isolate

LAS VEGAS, March 21, 2022 — With validation of its Novel Food application to the FSA, GVB Biopharma continues to strengthen its UK and European activities. GVB is one of the largest US CBD manufacturers and has several modern production facilities. GVB is one of the few true “seed to shelf” suppliers remaining in this space. GVB […]

  • Posted in
  • Comments Off on GVB Biopharma Strengthens European Operations After UK Validation

Get in touch today

Ready to Build Your Brand?

17